Claims
- 1. A peptide of the formula
- ACYL--X--Y--W--U (I)
- and the pharmaceutically acceptable acid addition salts thereof, wherein ACYL is DNMA, ##STR113## wherein R is hydrogen or a straight or branched lower alkyl of from one to six carbon atoms, ##STR114## X is HIS, HOMOHIS, PHE, HOMOPHE, ILE, LEU, NLE, N-MeHIS, N-MeLEU, or ##STR115## Y is STA, CYSTA, or PHSTA; W is LEU, ILE, N-MeLEU, N-MeILE, VAL or absent with the proviso that, when ACYL is DNMA, W is present; and
- U is --NHCH.sub.2 CH(CH.sub.3)CH.sub.2 CH.sub.3, --NHCH.sub.2 Ph, ##STR116## --NHCH.sub.2 CH(OH)CH.sub.2 SCH(CH.sub.3).sub.2, --NHCH.sub.2 CH(OH)CH.sub.2 SOCH(CH.sub.3).sub.2, --NHCH.sub.2 CH(OH)CH.sub.2 SO.sub.2 CH(CH.sub.3).sub.2, ##STR117##
- 2. A peptide according to claim 1 wherein
- U is --NHCH.sub.2 Ph, ##STR118## --NHCH.sub.2 CH.dbd.CH.sub.2, --NHCH.sub.2 CH(OH)CH.sub.2 SCH(CH.sub.3).sub.2, --NHCH.sub.2 CH(OH)CH.sub.2 SOCH(CH.sub.3).sub.2, --NHCH.sub.2 CH(OH)CH.sub.2 SO.sub.2 CH(CH.sub.3).sub.2, ##STR119## or --NHCH.sub.2 CH(CH.sub.3)CH.sub.2 CH.sub.3.
- 3. A peptide according to claim 1 wherein the peptide is a member selected from the group consisting of: and DNMA-HIS-STA-LEU-NHCH.sub.2 Ph, ##STR120## DNMA-(D-HIS)-STA-LEU-NHCH.sub.2 Ph, DNMA-HIS-STA-(D-LEU)-NHCH.sub.2 Ph,
- DNMA-(N-MeHIS)-STA-LEU-NHCH.sub.2 Ph,
- DNMA-HIS-STA-(N-MeLEU)-NHCH.sub.2 Ph,
- DNMA-HIS-CYSTA-LEU-NHCH.sub.2 Ph, ##STR121##
- 4. A compound named DNMA-HIS-STA-NHCH.sub.2 CH(OH)CH.sub.2 SO.sub.2 CH(CH.sub.3).sub.2.
- 5. A pharmaceutical composition comprising a renin-inhibitory effective amount of a compound as claimed in claim 4 together with a pharmaceutically acceptable carrier.
- 6. A method of treating renin-associated hypertension which comprises administering to a mammal a pharmaceutical composition comprising a renin inhibitory effective amount of a compound as in claim 1 together with a pharmaceutically acceptable carrier.
- 7. A method of treating renin-associated hypertension which comprises administering to a mammal a pharmaceutical composition as claimed in claim 5.
- 8. A method of treating hyperaldosteronism which comprises administering to a mammal a pharmaceutical composition comprising an hyperaldosteronism-inhibitory effective amount of a compound as claimed in claim 1 together with a pharmaceutically acceptable carrier.
- 9. A method of determining the presence of renin-associated hypertension in a patient which comprises administering to said patient, at a hypotensive dosage level and as a single dose, a peptide of claim 1, followed by monitoring of said patient's blood pressure.
- 10. A method of treating congestive heart failure which comprises administering to a mammal a pharmaceutical composition comprising an amount effective for treating congestive heart failure of a compound as claimed in claim 1 together with a pharmaceutically acceptable carrier.
CROSS-REFERENCE
This application is a continuation-in-part of copending application Ser. No. 941,966 filed Dec. 15, 1986, now U.S. Pat. No. 4,735,933.
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
4735933 |
Hudspeth et al. |
Apr 1988 |
|
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
941966 |
Jan 1986 |
|